doi: 10.1016/s2213-8587(15)00298-3
It may be appropriate for individuals with weight-loss resistance, insulin resistance, metabolic syndrome, PCOS, elevated cardiometabolic risk, or those who were unable to tolerate full-dose GLP-1 therapy
It retains the same two targets as tirzepatide but adds a critical third lever: GLP-1 Receptor Agonism: Drives central fullness and slows digestion
Nearly 4% of users who reported side effects mentioned menstrual changes, things like irregular cycles, heavy bleeding, or intermenstrual bleeding, and these symptoms arent prominently featured in the current prescribing information. When you consider that were looking at a mixed-gender sample on Reddit, and that Reddit skews male, the true rate among women taking these medications could potentially be higher, Sehgal said
Stability-Enhanced Design: Includes amino acid modifications to improve stability in experimental settings